Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
ACR-NKF consensus: gadolinium and kidney disease (2021 abstract)
Product / population
2021 ACR-NKF consensus abstract about the agents classified as group II/III in that publication; not a current all-agent classification table.
Renal method
Acute kidney injury, indexed eGFR below 30 and dialysis.
Source revision
2021; Kidney Medicine 3(1):142-150.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Gadolinium: existing-dialysis timing differs between dated sources
The 2021 ACR-NKF abstract regards dialysis alteration as generally unnecessary after its group II/III agents. UCSF seeks prompt hemodialysis, preferably within 24 hours, for existing dialysis patients. Both distinguish this from starting prophylactic dialysis.
What to reconcile: Reconcile the agent, date and local radiology/nephrology policy. Do not delay essential imaging or initiate dialysis automatically; no agent classification is inferred from a class name.
ACR and National Kidney Foundation / author institutional repository · 2021 ACR-NKF consensus abstract about the agents classified as group II/III in that publication; not a current all-agent classification table.
Renal method: Acute kidney injury, indexed eGFR below 30 and dialysis. Source date: 2021; Kidney Medicine 3(1):142-150. Retrieved: 2026-09-07
Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The consensus weighs the very low NSF risk of its group II agents against harm from withholding an essential examination. In AKI or eGFR below 30, delaying appropriate contrast imaging can pose greater harm. The abstract says initiating or changing dialysis solely because of group II/III administration is likely unnecessary. These are dated consensus statements, not a claim that every gadolinium agent is low-risk or that product-specific contraindications disappear. Only the primary-publication abstract was accessible through the authors' institutional repository; full-text tables were not independently re-reviewed.
RDM39-professional-gadoterate-clariscan-e3d8035084-C1 · Source locator: Abstract and publication details
Source-specific limits
Primary abstract only. DOI 10.1016/j.xkme.2020.10.001 as listed by the repository; full text access was challenged.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.